Jagdeep Nanchahal

Jagdeep undertook his PhD, funded by the MRC, whilst a medical student in London and trained as a reconstructive plastic surgeon. His research is focussed on identifying novel therapeutic targets for reducing fibrosis and promoting tissue regeneration, and translating his findings through to clinical trials. 

In 2013 his group identified TNF as therapeutic target for Dupuytren’s disease, a common fibrotic condition of the hand. He led successful phase 2a and 2b clinical trials of anti-TNF (adalimumab) for early-stage Dupuytren’s disease. The group went on to show that the treatment is likely to be cost effective.

He is co-applicant on a trial led by Prof Matt Costa at the Kadoorie Centre of anti-TNF for preventing postoperative delirium in patients undergoing surgery for hip fractures. 

His group has also identified a novel mechanism for promoting repair and regeneration of multiple tissues by targeting endogenous stem cells developed an engineered protein with a higher safety profile.

He is a proponent of evidence-based medicine and was a plastic surgery member of the NICE Development Groups on complex and non-complex fractures.